Informational

Data use:

We use cookies and similar tools to make your use of this website easy and to keep it working properly. We may share data about you and how you use the site with third parties, such as analytics and marketing partners. Learn more in our Privacy Policy and Terms of Use. By continuing to use the site, you agree to this.

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Aucatzyl® (obecabtagene autoleucel) – New orphan drug approval

November 8, 2024 - The FDA announced the approval of Autolus’ Aucatzyl (obecabtagene autoleucel), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Download PDF

© 2026 Optum, Inc. All rights reserved. Stock photos used.